Alkagin Paste in the Prevention of Radiation Dermatitis

Dr. Te Vuong

Status and phase: Terminated; Phase 2

Conditions: Anus Neoplasms; Urogenital Neoplasms; Rectal Neoplasms

Treatments: Other: Aveeno cream; Other: Alkagin paste

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01408407

11-052

Details and patient eligibility

About

The purpose of this study is to determine whether Alkagin paste is effective at preventing radiodermatitis in patients receiving external beam radiation therapy to the perineal area.

Enrollment: 2 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients receiving a dose of 45 Gy or more with concomitant chemotherapy to the perineal skin (for treatment of anal canal, low rectal or gynecological cancer).
• Patients able to understand and sign an informed consent form.
• Patients that do not have active connective tissue disorders.
• Patients 18 years or older.
• Patients that did not receive any previous radiation.
• Patients that do not have any known allergy to any ingredients of the Alkagin Paste
• Patients need to be able to apply the creams themselves or have help with applying the creams.
• Patients who have been offered to purchase silver clear underpants but have refused

Exclusion criteria

• Patients that have a type V or type VI skin type according to the Fitzpatrick scale (because these patients will likely have less radiodermatitis and if they do, it will be harder to evaluate it)

The Fitzpatrick Scale:

• Type I (scores 0-7) White; very fair; freckles. Always burns, never tans

• Type II (scores 8-16) White; fair. Usually burns, tans with difficulty

• Type III (scores 17-25) Beige; very common. Sometimes mild burn, gradually tans

• Type IV (scores 25-30) Beige with a brown tint; typical Mediterranean Caucasian skin. Rarely burns, tans with ease

• Type V (scores over 30) Dark brown. Very rarely burns, tans very easily

• Type VI Black. Never burns, tans very easily

  2. Patients with an allergic reaction to Alkagin Paste

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

2 participants in 2 patient groups

Arm A: standard of care

Active Comparator group

Description:

Patients will be asked to apply Aveeno cream twice a day starting the day of their treatment until two weeks after the end of their treatment

Treatment:

Other: Aveeno cream

Arm B: standard of care plus Alkagin paste

Experimental group

Description:

Patients will apply Alkagin Paste to the treatment area everyday one week before starting radiotherapy, throughout treatment and for two weeks post treatment. They will also perform standard of care skin treatment.

Treatment:

Other: Alkagin paste

Other: Aveeno cream